TN2013000346A1 - Asymmetric ureas and medical uses thereof - Google Patents

Asymmetric ureas and medical uses thereof

Info

Publication number: TN2013000346A1
Authority: TN; Tunisia
Prior art keywords: medical uses; asymmetric ureas; ureas; asymmetric; compounds
Prior art date: 2011-02-25

Application number

TNP2013000346A

Other languages

English (en)

Inventor

Rubio Silvina Garcia

Claudio Pietra

Claudio Giuliano

Zhigang Li

Original Assignee

Helsinn Healthcare Sa

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2011-02-25

Filing date

2013-08-16

Publication date

2015-01-20

2013-08-16 Application filed by Helsinn Healthcare Sa filed Critical Helsinn Healthcare Sa

2015-01-20 Publication of TN2013000346A1 publication Critical patent/TN2013000346A1/fr

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
- C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
- C07D211/36—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D211/56—Nitrogen atoms
- C07D211/58—Nitrogen atoms attached in position 4
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
- A61K31/4468—Non condensed piperidines, e.g. piperocaine having a nitrogen directly attached in position 4, e.g. clebopride, fentanyl
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
- A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
- A61K31/4525—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with oxygen as a ring hetero atom
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
- A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
- A61K31/4545—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring hetero atom, e.g. pipamperone, anabasine
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5375—1,4-Oxazines, e.g. morpholine
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/06—Anti-spasmodics, e.g. drugs for colics, esophagic dyskinesia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/14—Prodigestives, e.g. acids, enzymes, appetite stimulants, antidyspeptics, tonics, antiflatulents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
- A61P25/32—Alcohol-abuse
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
- A61P25/36—Opioid-abuse
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/48—Drugs for disorders of the endocrine system of the pancreatic hormones
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
- C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
- C07D211/36—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D211/60—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
- C07D211/92—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with a hetero atom directly attached to the ring nitrogen atom
- C07D211/94—Oxygen atom, e.g. piperidine N-oxide
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
- C07D211/92—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with a hetero atom directly attached to the ring nitrogen atom
- C07D211/96—Sulfur atom
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links

Landscapes

Health & Medical Sciences (AREA)
Chemical & Material Sciences (AREA)
Organic Chemistry (AREA)
Pharmacology & Pharmacy (AREA)
Life Sciences & Earth Sciences (AREA)
Veterinary Medicine (AREA)
Public Health (AREA)
General Health & Medical Sciences (AREA)
Animal Behavior & Ethology (AREA)
Medicinal Chemistry (AREA)
Chemical Kinetics & Catalysis (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
General Chemical & Material Sciences (AREA)
Engineering & Computer Science (AREA)
Bioinformatics & Cheminformatics (AREA)
Diabetes (AREA)
Epidemiology (AREA)
Hematology (AREA)
Obesity (AREA)
Cardiology (AREA)
Addiction (AREA)
Neurology (AREA)
Endocrinology (AREA)
Neurosurgery (AREA)
Heart & Thoracic Surgery (AREA)
Biomedical Technology (AREA)
Emergency Medicine (AREA)
Psychiatry (AREA)
Child & Adolescent Psychology (AREA)
Pulmonology (AREA)
Hospice & Palliative Care (AREA)
Urology & Nephrology (AREA)
Gastroenterology & Hepatology (AREA)
Orthopedic Medicine & Surgery (AREA)
Physical Education & Sports Medicine (AREA)
Nutrition Science (AREA)
Vascular Medicine (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Hydrogenated Pyridines (AREA)

TNP2013000346A 2011-02-25 2013-08-16 Asymmetric ureas and medical uses thereof TN2013000346A1 (en)

Applications Claiming Priority (3)

Application Number	Priority Date	Filing Date	Title
PCT/CN2011/000298 WO2012113103A1 (fr)	2011-02-25	2011-02-25	Urées asymétriques et leurs utilisations médicales
US201161466070P	2011-03-22	2011-03-22
PCT/US2012/026315 WO2012116176A2 (fr)	2011-02-25	2012-02-23	Urées asymétriques et utilisations médicales de celles-ci

Publications (1)

Publication Number	Publication Date
TN2013000346A1 true TN2013000346A1 (en)	2015-01-20

Family

ID=46719417

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
TNP2013000346A TN2013000346A1 (en)	2011-02-25	2013-08-16	Asymmetric ureas and medical uses thereof

Country Status (41)

Country	Link
US (3)	US8658797B2 (fr)
EP (1)	EP2678017B1 (fr)
JP (1)	JP6077468B2 (fr)
KR (2)	KR20140014186A (fr)
CN (2)	CN103874492B (fr)
AP (1)	AP3768A (fr)
AR (1)	AR085398A1 (fr)
AU (1)	AU2012220531B2 (fr)
BR (1)	BR112013021566B1 (fr)
CA (1)	CA2820767C (fr)
CL (1)	CL2013002412A1 (fr)
CO (1)	CO6771450A2 (fr)
CY (1)	CY1118947T1 (fr)
DK (1)	DK2678017T3 (fr)
DO (1)	DOP2013000195A (fr)
EA (1)	EA027374B1 (fr)
EC (1)	ECSP13012893A (fr)
ES (1)	ES2628386T3 (fr)
GE (1)	GEP20156319B (fr)
HR (1)	HRP20170997T1 (fr)
HU (1)	HUE035039T2 (fr)
IL (1)	IL227941A (fr)
LT (1)	LT2678017T (fr)
MA (1)	MA34968B1 (fr)
ME (1)	ME02845B (fr)
MX (1)	MX347587B (fr)
MY (1)	MY164354A (fr)
NI (1)	NI201300070A (fr)
PE (1)	PE20141000A1 (fr)
PH (1)	PH12013501757A1 (fr)
PL (1)	PL2678017T3 (fr)
PT (1)	PT2678017T (fr)
RS (1)	RS56033B1 (fr)
SG (1)	SG192138A1 (fr)
SI (1)	SI2678017T1 (fr)
SM (1)	SMT201700407T1 (fr)
TN (1)	TN2013000346A1 (fr)
TW (1)	TWI579273B (fr)
UA (1)	UA113510C2 (fr)
WO (2)	WO2012113103A1 (fr)
ZA (1)	ZA201307071B (fr)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
WO2012113103A1 (fr) *	2011-02-25	2012-08-30	Helsinn Healthcare S.A.	Urées asymétriques et leurs utilisations médicales
MX370720B (es)	2012-12-21	2019-12-20	Aveo Pharmaceuticals Inc	Anticuerpos anti-gdf15.
TWI690512B (zh) *	2014-03-07	2020-04-11	瑞士商赫爾辛保健股份有限公司	對位取代的不對稱脲及其醫療用途
RU2686317C2 (ru) *	2015-04-24	2019-04-25	Федеральное государственное бюджетное научное учреждение "Научно-исследовательский институт фармакологии имени В.В. Закусова"	Замещенные 1,2,5-триметил- и 2,2,6,6-тетраметил-4-аминопиперидины, обладающие антиишемическим действием
EP3390355B1 (fr)	2016-03-22	2022-12-28	Helsinn Healthcare S.A.	Urées asymétriques de benzènesulfonyle et leurs utilisations médicales
KR20200041336A (ko) *	2017-08-07	2020-04-21	고쿠리츠다이가쿠호진 히로시마다이가쿠	지방성 간 질환의 치료제 및 비만증의 치료제
WO2019040107A1 (fr)	2017-08-21	2019-02-28	Acadia Pharmaceuticals Inc.	Composés, sels correspondants et méthodes pour le traitement de maladies
US11440884B2 (en)	2017-08-21	2022-09-13	Acadia Pharmaceuticals Inc.	Compounds, salts thereof and methods for treatment of diseases
ES2910030T3 (es)	2017-12-11	2022-05-11	Helsinn Healthcare Sa	Sal de fumarato de (R)-3-(1-(2,3-dicloro-4-(pirazina-2-il)fenil)-2,2,2-trifluoroetil)-1-metil-1-(1-metilpiperidina-4-il) urea, métodos de preparación y usos de la misma
EP3542799A1 (fr)	2018-03-22	2019-09-25	Helsinn Healthcare SA	Nouvel agoniste de la ghréline centralement actif et ses utilisations médicales
PE20231987A1 (es)	2021-03-10	2023-12-12	Jnana Therapeutics Inc	Inhibidores de molecula pequena de la funcion de slc6a19 de mamifero
WO2022253941A1 (fr)	2021-06-02	2022-12-08	Helsinn Healthcare Sa	Dérivés d'urée de pipéridine destinés à être utilisés en tant qu'agents inotropes
US20240391928A1 (en) *	2021-09-22	2024-11-28	Duke University	Compositions for the treatment of food and chemical addiction and methods of making and using same
WO2024158862A1 (fr) *	2023-01-25	2024-08-02	University Of North Texas Health Science Center	Composés antioxydants de thio-urée à activité neuroprotectrice

Family Cites Families (43)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
JPS5285174A (en) *	1976-01-05	1977-07-15	Yoshitomi Pharmaceut Ind Ltd	Novel urea or thiourea derivatives
AU7545894A (en)	1993-09-02	1995-03-22	Yamanouchi Pharmaceutical Co., Ltd.	Carbamate derivative and medicine containing the same
AU3785597A (en)	1996-08-14	1998-03-06	Takeda Chemical Industries Ltd.	Cyclic urea compounds, their production and use as herbicides
US6399619B1 (en)	1999-04-06	2002-06-04	Merck & Co., Inc.	Pyrrolidine modulators of chemokine receptor activity
JP4664564B2 (ja) *	2000-03-06	2011-04-06	アカディアファーマシューティカルズ，インコーポレーテッド	セロトニン関連疾患の治療に使用する含窒素環式化合物
GB0011838D0 (en) *	2000-05-17	2000-07-05	Astrazeneca Ab	Chemical compounds
US20030022891A1 (en) *	2000-12-01	2003-01-30	Anandan Palani	MCH antagonists and their use in the treatment of obesity
JP2004520423A (ja)	2001-03-01	2004-07-08	アストラゼネカ・アクチエボラーグ	Ｃｃｒ５モジュレーターとしてのｎ−ピペリジニル化合物
GB0107228D0 (en)	2001-03-22	2001-05-16	Astrazeneca Ab	Chemical compounds
US6673829B2 (en) *	2001-09-14	2004-01-06	Novo Nordisk A/S	Aminoazetidine,-pyrrolidine and -piperidine derivatives
SE0103818D0 (sv)	2001-11-15	2001-11-15	Astrazeneca Ab	Chemical compounds
SE0200919D0 (sv)	2002-03-25	2002-03-25	Astrazeneca Ab	Chemical compounds
JP2006505531A (ja) *	2002-09-11	2006-02-16	メルク　エンド　カムパニー　インコーポレーテッド	メラノコルチン−４受容体作働薬としてのピペラジン尿素誘導体
WO2004046110A1 (fr)	2002-11-15	2004-06-03	Yamanouchi Pharmaceutical Co., Ltd.	Antagoniste du recepteur d'hormone de concentration de la melanine
WO2005000803A2 (fr) *	2003-06-30	2005-01-06	Sumitomo Chemical Co	Compose d'uree asymetrique et procede pour produire un compose asymetrique par reaction d'addition de conjugue asymetrique avec ledit compose comme catalyseur
US7115767B2 (en) *	2003-07-18	2006-10-03	Abbott Laboratories	Tetraline derivatives as ghrelin receptor modulators
JP2007522224A (ja) *	2004-02-10	2007-08-09	ジヤンセン・フアーマシユーチカ・ナームローゼ・フエンノートシヤツプ	α４インテグリン拮抗薬としてのピリダジノン尿素
US20050261278A1 (en) *	2004-05-21	2005-11-24	Weiner David M	Selective serotonin receptor inverse agonists as therapeutics for disease
GB0412865D0 (en)	2004-06-09	2004-07-14	Glaxo Group Ltd	Chemical compounds
SE0401657D0 (sv)	2004-06-24	2004-06-24	Astrazeneca Ab	Chemical compounds
SE0401971D0 (sv) *	2004-08-02	2004-08-02	Astrazeneca Ab	Piperidne derivatives
AU2005272627A1 (en) *	2004-08-13	2006-02-23	Amgen Inc.	Substituted benzofused heterocycles
EP1804785A2 (fr) *	2004-10-27	2007-07-11	Neurogen Corporation	Diaryl urees, antagonistes du cb1
US20080306055A1 (en)	2004-12-21	2008-12-11	Astrazeneca Ab	Heterocyclic Mchr1 Antagonists And Their Use In Therapy
US7829589B2 (en)	2005-06-10	2010-11-09	Elixir Pharmaceuticals, Inc.	Sulfonamide compounds and uses thereof
WO2007029086A2 (fr) *	2005-09-05	2007-03-15	Ranbaxy Laboratories Limited	Derives de 3-azabicyclo[3.1.0]hexane en tant qu'inhibiteurs de la dipeptidyl peptidase-iv
EP1948190A2 (fr) *	2005-11-01	2008-07-30	Transtech Pharma	Utilisation pharmaceutique des amides substitués
AR058277A1 (es) *	2005-12-09	2008-01-30	Solvay Pharm Gmbh	N- sulfamoil - piperidin - amidas, composiciones farmaceuticas que las comprenden y procedimiento para su preparacion
JP2009542809A (ja)	2006-07-12	2009-12-03	メルクエンドカムパニーインコーポレーテッド	グレリン受容体アンタゴニストとしての置換ピラゾール
JP2008042298A (ja)	2006-08-02	2008-02-21	Olympus Corp	固体撮像装置
GB0701992D0 (en)	2007-02-02	2007-03-14	7Tm Pharma As	Grehlin Receptor Modulators
US20080280886A1 (en) *	2007-05-08	2008-11-13	Auspex Pharmaceuticals, Inc.	Substituted ureas
GB0710865D0 (en)	2007-06-06	2007-07-18	Glaxo Group Ltd	Novel compounds
GB0710863D0 (en)	2007-06-06	2007-07-18	Glaxo Group Ltd	Novel compounds
WO2009020960A1 (fr)	2007-08-06	2009-02-12	The Regents Of The University Of California	Préparation d'urées 1,3-substituées novatrices en tant qu'inhibiteurs d'époxyde hydrolase soluble
WO2009039460A2 (fr) *	2007-09-21	2009-03-26	Acadia Pharmaceuticals, Inc.	Co-administration de pimavansérine avec d'autres agents
UA100527C2 (en) *	2007-10-10	2013-01-10	Астразенека Аб	Benzothiazoles as ghrelin receptor modulators
WO2009089659A1 (fr)	2008-01-18	2009-07-23	Shanghai Targetdrug Co., Ltd.	Composés à base de pyrollidine
WO2009092293A1 (fr)	2008-01-18	2009-07-30	Shanghai Targetdrug Co., Ltd.	Composés à base de pyrollidine
US8592454B2 (en) *	2008-09-19	2013-11-26	Takeda Pharmaceutical Company Limited	Nitrogen-containing heterocyclic compound and use of same
WO2010111353A1 (fr) *	2009-03-25	2010-09-30	Acadia Pharmaceuticals, Inc.	Dérivés de pipéridine n-substitués en tant qu'agents spécifiques des récepteurs de la sérotonine
WO2011060397A1 (fr) *	2009-11-16	2011-05-19	Schering Corporation	Amino heterocycles substitues utilises comme antagonistes du vih
WO2012113103A1 (fr) *	2011-02-25	2012-08-30	Helsinn Healthcare S.A.	Urées asymétriques et leurs utilisations médicales

2011
- 2011-02-25 WO PCT/CN2011/000298 patent/WO2012113103A1/fr not_active Ceased
2012
- 2012-02-23 KR KR1020137025184A patent/KR20140014186A/ko not_active Withdrawn
- 2012-02-23 EP EP12749383.1A patent/EP2678017B1/fr active Active
- 2012-02-23 RS RS20170546A patent/RS56033B1/sr unknown
- 2012-02-23 CN CN201280008805.XA patent/CN103874492B/zh active Active
- 2012-02-23 PH PH1/2013/501757A patent/PH12013501757A1/en unknown
- 2012-02-23 MY MYPI2013003013A patent/MY164354A/en unknown
- 2012-02-23 JP JP2013555559A patent/JP6077468B2/ja active Active
- 2012-02-23 ES ES12749383.1T patent/ES2628386T3/es active Active
- 2012-02-23 LT LTEP12749383.1T patent/LT2678017T/lt unknown
- 2012-02-23 PT PT127493831T patent/PT2678017T/pt unknown
- 2012-02-23 MA MA36252A patent/MA34968B1/fr unknown
- 2012-02-23 PL PL12749383T patent/PL2678017T3/pl unknown
- 2012-02-23 UA UAA201311289A patent/UA113510C2/uk unknown
- 2012-02-23 AU AU2012220531A patent/AU2012220531B2/en active Active
- 2012-02-23 HR HRP20170997TT patent/HRP20170997T1/hr unknown
- 2012-02-23 AP AP2013007123A patent/AP3768A/en active
- 2012-02-23 GE GEAP201213239A patent/GEP20156319B/en unknown
- 2012-02-23 CN CN201611088800.9A patent/CN106995403B/zh active Active
- 2012-02-23 SG SG2013056775A patent/SG192138A1/en unknown
- 2012-02-23 EA EA201300946A patent/EA027374B1/ru unknown
- 2012-02-23 MX MX2013006974A patent/MX347587B/es active IP Right Grant
- 2012-02-23 CA CA2820767A patent/CA2820767C/fr active Active
- 2012-02-23 SI SI201230981A patent/SI2678017T1/sl unknown
- 2012-02-23 WO PCT/US2012/026315 patent/WO2012116176A2/fr not_active Ceased
- 2012-02-23 BR BR112013021566-6A patent/BR112013021566B1/pt active IP Right Grant
- 2012-02-23 PE PE2013001934A patent/PE20141000A1/es active IP Right Grant
- 2012-02-23 SM SM20170407T patent/SMT201700407T1/it unknown
- 2012-02-23 KR KR1020187017910A patent/KR101907573B1/ko active Active
- 2012-02-23 HU HUE12749383A patent/HUE035039T2/en unknown
- 2012-02-23 DK DK12749383.1T patent/DK2678017T3/en active
- 2012-02-23 ME MEP-2017-123A patent/ME02845B/fr unknown
- 2012-02-24 TW TW101106171A patent/TWI579273B/zh active
- 2012-02-24 AR ARP120100611A patent/AR085398A1/es active IP Right Grant
- 2012-02-24 US US13/404,165 patent/US8658797B2/en active Active
2013
- 2013-08-13 IL IL227941A patent/IL227941A/en active IP Right Grant
- 2013-08-15 NI NI201300070A patent/NI201300070A/es unknown
- 2013-08-16 TN TNP2013000346A patent/TN2013000346A1/fr unknown
- 2013-08-21 CL CL2013002412A patent/CL2013002412A1/es unknown
- 2013-08-23 DO DO2013000195A patent/DOP2013000195A/es unknown
- 2013-09-19 ZA ZA2013/07071A patent/ZA201307071B/en unknown
- 2013-09-24 EC EC2013012893A patent/ECSP13012893A/es unknown
- 2013-09-24 CO CO13226995A patent/CO6771450A2/es unknown
2014
- 2014-01-08 US US14/150,360 patent/US9751836B2/en active Active
2017
- 2017-06-19 CY CY20171100635T patent/CY1118947T1/el unknown
- 2017-07-30 US US15/663,761 patent/US10407390B2/en active Active

Also Published As

Publication number	Publication date
US20140121210A1 (en)	2014-05-01
BR112013021566A2 (pt)	2016-11-08
SMT201700407T1 (it)	2017-09-07
US20180044293A1 (en)	2018-02-15
ZA201307071B (en)	2014-06-25
MX347587B (es)	2017-05-03
WO2012116176A3 (fr)	2014-04-24
ECSP13012893A (es)	2013-11-29
KR20140014186A (ko)	2014-02-05
US10407390B2 (en)	2019-09-10
HUE035039T2 (en)	2018-05-02
UA113510C2 (uk)	2017-02-10
WO2012116176A2 (fr)	2012-08-30
CO6771450A2 (es)	2013-10-15
PH12013501757A1 (en)	2013-10-14
JP2014518543A (ja)	2014-07-31
BR112013021566B1 (pt)	2020-11-17
IL227941A (en)	2017-10-31
DOP2013000195A (es)	2014-12-15
CN103874492A (zh)	2014-06-18
US8658797B2 (en)	2014-02-25
ES2628386T3 (es)	2017-08-02
RS56033B1 (sr)	2017-09-29
US20120220629A1 (en)	2012-08-30
LT2678017T (lt)	2017-06-26
KR20180075703A (ko)	2018-07-04
AP3768A (en)	2016-08-31
MX2013006974A (es)	2013-10-07
EA027374B1 (ru)	2017-07-31
NI201300070A (es)	2014-03-11
AU2012220531B2 (en)	2017-02-23
US9751836B2 (en)	2017-09-05
EP2678017B1 (fr)	2017-04-05
CA2820767C (fr)	2019-06-25
PL2678017T3 (pl)	2017-09-29
CN103874492B (zh)	2016-12-07
MY164354A (en)	2017-12-15
NZ615283A (en)	2015-09-25
EP2678017A4 (fr)	2015-05-20
GEP20156319B (en)	2015-07-10
ME02845B (fr)	2018-01-20
CN106995403B (zh)	2020-04-24
CN106995403A (zh)	2017-08-01
KR101907573B1 (ko)	2018-10-15
TW201245151A (en)	2012-11-16
EA201300946A1 (ru)	2014-06-30
PE20141000A1 (es)	2014-08-09
CY1118947T1 (el)	2018-01-10
PT2678017T (pt)	2017-06-26
WO2012113103A1 (fr)	2012-08-30
TWI579273B (zh)	2017-04-21
AR085398A1 (es)	2013-09-25
MA34968B1 (fr)	2014-03-01
CA2820767A1 (fr)	2012-08-30
SI2678017T1 (sl)	2017-07-31
AU2012220531A1 (en)	2013-09-26
JP6077468B2 (ja)	2017-02-08
EP2678017A2 (fr)	2014-01-01
HRP20170997T1 (hr)	2017-10-06
SG192138A1 (en)	2013-08-30
IL227941A0 (en)	2013-09-30
CL2013002412A1 (es)	2014-02-07
DK2678017T3 (en)	2017-07-24
AP2013007123A0 (en)	2013-09-30

Publication	Publication Date	Title
TN2013000346A1 (en)	2015-01-20	Asymmetric ureas and medical uses thereof
PH12014501199A1 (en)	2014-09-08	Substituted 4-phenyl - pyridines for the treatment of nk-1 receptor related diseases
MY151246A (en)	2014-04-30	Benzofuranyl derivatives
EA024842B9 (ru)	2017-08-31	Соединения в качестве модуляторов протеинкиназы pi3k
PH12016501192B1 (en)	2016-08-15	Tetrahydropyridopyrazines modulators of gpr6
IN2012DN00971A (fr)	2015-04-10
PH12015500376B1 (en)	2015-04-20	Novel bicyclic pyridinones
GEP20135933B (en)	2013-10-10	Compounds as bradykinin b1 antagonists
GEP20156318B (en)	2015-07-10	Heteroaryl derivatives as alpha7 nachr modulators
MX2016007128A (es)	2016-08-11	Compuestos del receptor 6 de quimiocina (ccr6).
PH12016501483A1 (en)	2016-08-22	P-substituted asymmetric ureas and medical uses thereof
CA2878796C (fr)	2018-10-23	Derives de pyridinone comme inhibiteurs de la transglutaminase tissulaire
AU2011279845A8 (en)	2014-11-20	Novel pyrrolidine derived beta 3 adrenergic receptor agonists
MX2014003883A (es)	2014-08-27	Inhibidores de monoacilglicerol lipasa para el tratamiento de enfermedades metabolicas y transtornos relacionados.
MX2013009386A (es)	2013-08-29	Nuevos compuestos de azaespirodecanona.
MX352874B (es)	2017-12-13	Composiciones, sintesis, y metodos para usar derivados de fenilcicloalquilmetilamina.
TN2013000441A1 (en)	2015-03-30	3-spirocyclic piperidine derivatives as ghrelin receptor agonists
PH12017501147A1 (en)	2018-03-05	Total synthesis of trioxacarcin dc-45-a2 and preparation of trioxacarcin analogs
WO2013175347A3 (fr)	2014-01-30	Compositions et méthodes pour le traitement de troubles respiratoires
MX2016009250A (es)	2016-09-15	Nuevos imidazoles para el tratamiento y profilaxis de la infeccion por virus sincicial respiratorio.
TN2013000150A1 (en)	2014-11-10	Co-crystals and salts of ccr3-inhibitors